Entera Appoints Dr. Riccardo Camisasca as Chief Medical Officer
Entera M.D. appoints Dr. Riccardo Camisasca, a veteran pharmaceutical executive, to lead its upcoming Phase 3 trial of the oral osteoporosis treatment EB613. Appointment underscores management focus on late-stage clinical development.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day